Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120,138,422
-
Total 13F shares
-
33,776,828
-
Share change
-
+1,093,678
-
Total reported value
-
$1,021,408,758
-
Price per share
-
$30.24
-
Number of holders
-
55
-
Value change
-
+$33,104,673
-
Number of buys
-
32
-
Number of sells
-
14
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q2 2020
As of 30 Jun 2020,
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,776,828 shares.
The largest 10 holders included
FRAZIER MANAGEMENT LLC, FMR LLC, ORBIMED ADVISORS LLC, Bain Capital Life Sciences Investors, LLC, BlackRock Inc., Vivo Capital, LLC, RA CAPITAL MANAGEMENT, L.P., PRICE T ROWE ASSOCIATES INC /MD/, Omega Fund Management, LLC, and WELLS FARGO & COMPANY/MN.
This page lists
55
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.